Pharmaceutical

Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate

According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.

Sep 23, 2023 - 20:00
Alvotech’s AVT05 in phase III rheumatoid arthritis study, as the sole candidate
According to GlobalData, the number of individuals affected by rheumatoid arthritis is anticipated to rise to 6,980,823 cases by 2029.
Read the original article

Tags:

Previous Article

Over half of world’s population not covered by essential healthcare services

Next Article

JURA Bio and Syena partner to develop TCR-based therapies

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD and HD chorea

FDA approves Teva Pharmaceuticals’ AUSTEDO XR for TD an...

May 31, 2024

STAT+: Health tech’s 2024 hiring outlook: Balance tips toward employers

STAT+: Health tech’s 2024 hiring outlook: Balance tips ...

Jan 4, 2024

Eli Lilly reiterates POINT acquisition plans with tender offer extension

Eli Lilly reiterates POINT acquisition plans with tende...

Nov 12, 2023